当前位置:首页 - 行情中心 - 津膜科技(300334) - 财务分析 - 利润表

津膜科技

(300334)

  

流通市值:23.56亿  总市值:23.56亿
流通股本:3.02亿   总股本:3.02亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入162,658,964.4107,419,534.5849,506,666.59245,942,425.69
  营业收入162,658,964.4107,419,534.5849,506,666.59245,942,425.69
二、营业总成本180,611,554.58121,964,915.1358,300,473.64277,234,384.98
  营业成本103,104,618.7269,209,731.1231,321,004.38180,065,123.47
  税金及附加2,519,819.41,975,405.93844,490.633,862,708.49
  销售费用16,084,961.3611,418,920.667,074,385.3614,453,106.34
  管理费用34,667,059.5223,563,764.9211,446,934.9946,383,563.69
  研发费用18,688,910.4212,389,368.215,747,722.7325,398,137.02
  财务费用5,546,185.163,407,724.291,865,935.557,071,745.97
  其中:利息费用6,534,636.674,385,060.521,975,641.238,605,743.24
  其中:利息收入-970,364.19-922,541.6-100,721.38800,621.33
三、其他经营收益
  加:公允价值变动收益529,578.89409,996.56--1,879,150.9
  加:投资收益995,032.74744,402.27533,401.949,579,536.6
  资产处置收益-121,163.068,769.729,977.52289,836.8
  资产减值损失(新)59,005.5329,147.45-40,391.414,996,641.43
  信用减值损失(新)15,708,515.1610,354,033.4610,655,079.2522,311,804.66
  其他收益539,044.4283,996.5181,438.323,285,965.72
四、营业利润-242,576.52-2,715,034.592,545,698.577,292,675.02
  加:营业外收入4,697,753.274,673,762.2965,065.284,759,282.84
  减:营业外支出190,305.3323,222.0323,222.0320,993.12
五、利润总额4,264,871.421,935,505.672,587,541.8212,030,964.74
  减:所得税费用1,446,066.631,073,620.49557,411.752,560,379.19
六、净利润2,818,804.79861,885.182,030,130.079,470,585.55
(一)按经营持续性分类
  持续经营净利润2,818,804.79-2,030,130.079,470,585.55
(二)按所有权归属分类
  归属于母公司股东的净利润1,341,019.47215,162.591,724,423.2811,047,411.82
  少数股东损益1,477,785.32646,722.59305,706.79-1,576,826.27
  扣除非经常损益后的净利润-17,999,847.08-15,392,893.79-8,769,589.44-21,975,599.19
七、每股收益
  (一)基本每股收益000.010.04
  (二)稀释每股收益000.010.04
八、其他综合收益----860,885.47
  归属于母公司股东的其他综合收益----860,885.47
九、综合收益总额2,818,804.79861,885.182,030,130.078,609,700.08
  归属于母公司股东的综合收益总额1,341,019.47215,162.591,724,423.2810,186,526.35
  归属于少数股东的综合收益总额1,477,785.32646,722.59305,706.79-1,576,826.27
公告日期2025-10-232025-08-262025-04-212025-04-21
审计意见(境内)标准无保留意见
TOP↑